Seoul National University College of Medicine Reports Findings in Lung Cancer (Association Between Angiotensin II Receptor Blockers and the Risk of Lung Cancer Among Patients With Hypertension From the Korean National Health Insurance …)

2020 DEC 23 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Business Daily -- New research on Oncology - Lung Cancer is the subject of a report. According to news reporting from Seoul, South Korea, by NewsRx journalists, research stated, “The objective of this study was to estimate the risk of lung cancer in relation to angiotensin II receptor blocker (ARB) use among patients with hypertension from the Korean National Health Insurance Service-National Health Screening Cohort. We conducted a retrospective cohort study of patients with hypertension who started to take antihypertensive medications and had a treatment period of at least 6 months.”

Financial support for this research came from Korean Foundation for Cancer Research.

The news correspondents obtained a quote from the research from the Seoul National University College of Medicine, “We calculated the weighted hazard ratios (HRs) and their 95% confidence intervals (CIs) of lung cancer associated with ARB use compared with calcium channel blocker (CCB) use using inverse probability treatment weighting. Among a total of 60 469 subjects with a median follow-up time of 7.8 years, 476 cases of lung cancer were identified. ARB use had a protective effect on lung cancer compared with CCB use (HR, 0.75; 95% CI, 0.59 to 0.96). Consistent findings were found in analyses considering patients who changed or discontinued their medication (HR, 0.50; 95% CI, 0.32 to 0.77), as well as for women (HR, 0.56; 95% CI, 0.34 to 0.93), patients without chronic obstructive pulmonary disease (HR, 0.75; 95% CI, 0.56 to 1.00), never-smokers (HR, 0.64; 95% CI, 0.42 to 0.99), and non-drinkers (HR, 0.69; 95% CI, 0.49 to 0.97). In analyses with different comparison antihypertensive medications, the overall protective effects of ARBs on lung cancer risk remained consistent. The results of the present study suggest that ARBs could decrease the risk of lung cancer.”

According to the news reporters, the research concluded: “More evidence is needed to establish the causal effect of ARBs on the incidence of lung cancer.”

For more information on this research see: Association Between Angiotensin II Receptor Blockers and the Risk of Lung Cancer Among Patients With Hypertension From the Korean National Health Insurance Service-National Health Screening Cohort. Journal of Preventive Medicine and Public Health = Yebang Uihakhoe Chi, 2020;53(6):476-486.

Our news journalists report that additional information may be obtained by contacting Hae-Young Lee, Division of Cardiology, Dept. of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. Additional authors for this research include Sungji Moon, Jieun Jang and Sue K. Park.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.3961/jpmph.20.405. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)